AveXis Reports Topline Results from Phase 1 Trial of SMA Type 1 Gene Therapy - Drug Discovery and Development
Zolgensma® – TreatSMA
AveXis Receives FDA Breakthrough Therapy Designation for AVXS-101 (Gene Therapy) for SMA - Cure SMA
A 2nd Patient Death Reported in Novartis' Gene Therapy Trial | BioSpace
The world's most expensive drug?
AveXis discloses data on AVXS-101 efficacy in treating early onset spinal muscular atrophy – TreatSMA
Avexis — PBM Capital
AveXis Gene Therapy Manufacturing Facility, North Carolina, USA
Another Zolgensma red flag, another delay in data reporting at Novartis' AveXis | Fierce Pharma
AveXis discloses data on AVXS-101 efficacy in treating early onset spinal muscular atrophy – TreatSMA
AveXis's House Of Cards: Dubious Trials, Drug Lawsuit And Fraud Allegations - Strong Sell With 94% Downside (NASDAQ:AVXS) | Seeking Alpha
FDA Places Partial Clinical Hold on Some Trials of Novartis Gene Therapy
AveXis' Lone-Drug Bubble - Much Ado About Nothing? (NASDAQ:AVXS) | Seeking Alpha
AveXIS Announcement – Utah Program for Inherited Neuromuscular Disorders
AveXis Brings $55M Gene Therapy Factory, 200 Jobs to Durham
Patient death in Novartis gene therapy trial unrelated to treatment, subsidiary says - MedCity News
AveXis chooses BIA Separations to support gene therapy pipeline
25 Up-and-Coming Gene Therapies of 2019
AveXis Inc.: Buy at the High? | The Motley Fool
AveXis Brings $55M Gene Therapy Factory, 200 Jobs to Durham
g925518.jpg
FDA Accepts AveXis' BLA for SMA Drug Zolgensma Under Priority Review - Muscular Dystrophy Association
AveXis's House Of Cards: Dubious Trials, Drug Lawsuit And Fraud Allegations - Strong Sell With 94% Downside (NASDAQ:AVXS) | Seeking Alpha
With new AveXis name, Novartis spotlights marquee role for gene therapy business | Fierce Pharma
AveXis Knew of 'Manipulated' Data in Zolgensma Application, FDA Says
AveXis' Lone-Drug Bubble - Much Ado About Nothing? (NASDAQ:AVXS) | Seeking Alpha
